Sofosbuvir
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Sofosbuvir: From Hepatitis C Virus Infection to Hepatitis B Virus Infection
One-Sentence Summary
Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor, whose established clinical use (per the clinical trial evidence in this pack) is chronic hepatitis C virus (HCV) infection. The TxGNN model predicts it may also be effective for Hepatitis B Virus Infection, with 50 clinical trials and 19 publications currently linked to this prediction — however, most of this evidence describes HCV treatment in HCV/HBV-coinfected patients or HBV reactivation safety signals, rather than direct antiviral efficacy against HBV itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hepatitis C virus (HCV) infection (evidenced by the drug’s extensive HCV clinical trial record in this pack; not recorded in Danish regulatory data, which shows no licenses) |
| Predicted New Indication | Hepatitis B Virus Infection |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L3 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (marked as a High-severity data gap). Based on the information available, sofosbuvir is a nucleotide prodrug that inhibits the HCV NS5B RNA-dependent RNA polymerase, and its efficacy in chronic HCV infection is extensively documented in the clinical trial evidence collected for this evaluation.
The mechanistic link to hepatitis B, however, is weak. HBV is a hepadnavirus — a DNA virus that replicates via reverse transcription — which is fundamentally different from the HCV NS5B RNA polymerase that sofosbuvir specifically targets. There is no direct evidence of anti-HBV antiviral activity in the evidence pack. The majority of the linked clinical trials and publications are actually HCV treatment studies in patients coinfected with HBV, or observational studies of HBV reactivation occurring after HCV is cleared with direct-acting antivirals (a safety signal, not an efficacy signal).
One relevant exception exists: a completed Phase 2 open-label pilot study (NCT03312023 / PMID 36045503) tested ledipasvir/sofosbuvir specifically in HBV mono-infected subjects, based on the observation that HBsAg had modestly declined in HCV/HBV-coinfected patients treated with the same regimen. This provides a plausible but still preliminary rationale — it is hypothesis-generating rather than confirmatory.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03312023 | Phase 2 | Completed | 21 | Open-label pilot of ledipasvir/sofosbuvir for 12 weeks in HBV mono-infected subjects; primary/secondary endpoints were HBsAg and HBV DNA decline at Week 12 |
| NCT02613871 | Phase 3b | Completed | 111 | LDV/SOF fixed-dose combination for 12 weeks in genotype 1/2 HCV patients coinfected with HBV in Taiwan; evaluated antiviral efficacy, safety, tolerability (primarily an HCV efficacy trial) |
| NCT02555943 | Phase 2/3 | Completed | 23 | Prospective study of incidence, morbidity, mortality and predisposing factors for HBV reactivation during direct-acting antiviral treatment of HCV/HBV coinfection |
| NCT03261349 | Phase 2 | Unknown | 21 | Pilot study of ledipasvir/sofosbuvir for HCV-associated indolent B-cell lymphoma; title references HBV subjects but relevance graded uncertain (Grade B) |
| NCT04997564 | Phase 4 | Unknown | 120 | SOF/VEL regimen combined with prophylactic tenofovir alafenamide (TAF) for treatment-naïve HCV/HBV coinfected patients, to prevent HBV reactivation |
| NCT02768961 | Phase 4 | Completed | 64 | JAILFREE-C: screening and prevalence study of HCV, HBV and HIV in a prison population, with evaluation of an interferon-free antiviral regimen |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36045503 | 2023 | Phase 2 open-label | Journal of Medical Virology | Pilot study of ledipasvir/sofosbuvir in HBV mono-infected subjects; hypothesized HBsAg decline based on prior coinfection data |
| 31722032 | 2020 | Cohort | Transactions of the Royal Society of Tropical Medicine and Hygiene | Sofosbuvir/daclatasvir therapy in chronic HCV and HCV/HBV coinfected patients in Egypt (treatment target was HCV) |
| 34864948 | 2022 | Cohort | Clinical Infectious Diseases | LDV/SOF in HCV/HBV coinfected patients in Taiwan; 108-week follow-up on HBV reactivation after HCV treatment |
| 29334502 | 2018 | Cohort | Journal of Clinical Gastroenterology | Risk of HBV reactivation among patients treated with ledipasvir/sofosbuvir for HCV infection |
| 33031326 | 2020 | Case report/review | Medicine | HBV reactivation after successful HCV treatment with sofosbuvir and ribavirin |
| 31632097 | 2019 | Cohort | Infection and Drug Resistance | Management of HBV reactivation post-DAA treatment in HCV/HBV coinfected patients |
| 33523503 | 2021 | Prospective observational | Journal of Viral Hepatitis | HBV reactivation in cancer patients receiving DAAs for HCV infection |
| 37517414 | 2023 | Modelling study | The Lancet Gastroenterology & Hepatology | Global prevalence, cascade of care and prophylaxis coverage of HBV (epidemiology, not treatment evidence) |
Denmark Market Information
Sofosbuvir currently holds no marketing authorisations in the Danish regulatory data reviewed (market status: not marketed; 0 licenses on record).
Safety Considerations
No structured safety data (key warnings, contraindications, or drug interaction records) is available for sofosbuvir in this evidence pack, and the Danish label/warning data required for a formal safety review is flagged as a blocking data gap. Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Separately, as an evidence-based observation from the literature review above (not a formal label warning): multiple studies report HBV reactivation in HCV/HBV coinfected patients following direct-acting antiviral treatment of HCV — this is a recurring safety signal that should be considered in any future evaluation of sofosbuvir for HBV-related indications.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale is weak — HBV and HCV use fundamentally different replication machinery, and sofosbuvir’s validated target (HCV NS5B polymerase) has no established activity against HBV. Most of the linked clinical and literature evidence reflects HCV treatment in coinfected patients or HBV reactivation safety observations, not direct antiviral efficacy against HBV. The one directly relevant trial (a small, open-label Phase 2 pilot) is hypothesis-generating rather than confirmatory. A blocking data gap on Danish product labeling also prevents even an initial safety assessment (S1).
To proceed, the following is needed:
- Danish/EU product label (SmPC) warnings, contraindications and DDI data (currently a blocking gap)
- Confirmed mechanism of action and original indication documentation for sofosbuvir
- A larger, controlled trial directly evaluating antiviral efficacy against HBV (the current evidence is limited to a small open-label pilot)
- Further characterization of the HBV reactivation risk signal before considering any coinfection-related use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.